Photochemistry for the preparation of biologic grafts--allografts and xenografts

• US 5,824,080 A
• Filed: 09/04/1996
• Issued: 10/20/1998
• Est. Priority Date: 09/28/1995
• Status: Expired due to Fees

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Lamuraglia, Glenn M.
• Primary Examiner(s): ISABELLA, DAVID J
• Application Number:
  US08/708,376
• Time in Patent Office: 776 Days
• Field of Search: 623/1, 623/2, 623/11, 623/12, 623/66, 435/240.23, 128/898, 604/21
• US Class Current: 424/423
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 41/0023 Agression treatment or altering
• CPC Class Codes: A61L 2300/224 containing metals, e.g. porphyrins, vitamin B12
• CPC Class Codes: A61L 2300/442 Colorants, dyes
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence

Abstract

Photodynamic therapy (PDT), a technique to produce cytotoxic free radicals, was used to prepare arterial allografts. After impregnation with the photo-sensitizer chloroaluminum sulfonated phthalocyanine, aortas of ACI rats were PDT-treated and transplanted in Lewis rats. PDT grafts were completely reendothelialized by 4 weeks.

Claims

1. A method for reducing host rejection of a biologic graft, said method comprising the steps of:

(a) contacting a tissue graft with a photosensitizing compound, and

(b) exposing said graft to electromagnetic radiation for a predetermined time and in an amount effective to transform the photosensitizing compound into an excited state, wherein said exposure results in the activation of the photosensitizing compound to produce an activated free-radical moiety which causes the death of rejection-inducing cells of the graft.

2. The method of claim 1, wherein said graft comprises an extracellular matrix and an amorphous ground substance comprising at least one proteoglycan or glycosaminoglycan.

3. The method of claim 1, wherein said photosensitizing compound is a sulfonated chloroaluminum phthalocyanine, bacteriochlorophyll a, benzophorphyrin derivative-monoacid, mono-L-aspartyl chlorine 6, N'"'"'-bis(2-ethyl-1,3-dioxolane)kryptocyanine, or dihematoporphyrin ether.

4. The method of claim 1, wherein the wavelength of said electromagnetic radiation is between 180 and 800 nanometers.

5. The method of claim 1, wherein said graft is an allograft or xenograft.

6. The method of claim 1, wherein said graft is selected from the group consisting of artery, vein, cardiac valve, capsular tissue, tendon, ligament, cartilaginous tissue, bone, skin, intraocular lens, corneal tissue, vascular tissue, and cardiac tissue.

7. The method of claim 6, wherein said graft is an artery or vein.